Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H31N3O6S |
InChIKeyVUSXKXGCZNKQFS-SANMLTNESA-N |
CAS Registry1609138-51-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 09 Feb 2017 |